Colorectal cancer is amongst the most common malignancy found in the Western world and usually ranks high in incidence and mortality among malignancies in those countries. Globally, colorectal cancers accounted for about 1 million new cases.
There is evidence that research contributes directly to improve the care of patients with colorectal cancer by more accurately refining prognosis and selecting the most appropriate adjuvant therapy for individual patients with colorectal carcinoma. In order to do this, our research focuses on studying novel tissue-based prognostic indicators at the molecular level.